Form 4: HealthEquity EVP Sells Shares Under 10b5-1 Plan
Insider Transaction Report
HealthEquity's EVP, General Counsel, Delano Ladd, sold 6,000 shares of common stock on September 19, 2025, through a pre-arranged 10b5-1 trading plan.
Summary
- Delano Ladd, Executive Vice President and General Counsel of HealthEquity, Inc. (HQY), reported the sale of common stock.
- The transactions involved the disposition of 6,000 shares of HealthEquity common stock.
- The sales occurred on September 19, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2025.
- The shares were sold in multiple transactions at weighted average prices of $93.9137 (5,000 shares), $95.0603 (971 shares), and $95.7 (29 shares).
- Following these reported transactions, Delano Ladd beneficially owns 79,456 shares of HealthEquity common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The sale of shares by an executive is a common occurrence, especially when conducted under a pre-arranged 10b5-1 trading plan, which mitigates concerns about opportunistic selling based on non-public information.
Negatives
- The sale of shares by an executive, even under a 10b5-1 plan, reduces their direct equity stake in the company.
Industry Context
This filing reports a routine insider stock transaction and does not provide information related to broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. This demonstrates adherence to SEC regulations for insider trading. | 06/12/2025 | The use of a 10b5-1 plan provides transparency and reduces the perception of opportunistic insider trading, aligning with good corporate governance practices. |
Stakeholder Impact
- Shareholders: The sale of shares by an executive slightly reduces their direct equity alignment with the company, but the pre-planned nature of the transaction under Rule 10b5-1 typically minimizes negative interpretations regarding management's confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/12/2025 | Date Rule 10b5-1 trading plan was adopted by the reporting person. |
| 09/19/2025 | Date of reported stock transactions (sales). |
| 09/22/2025 | Signature date of the Form 4 filing. |
Keywords
HealthEquity, HQY, Delano Ladd, Insider Trading, SEC Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.